Anti-TNF, a magic bullet in cancer immunotherapy?
Anne Montfort, Carine Dufau, Céline Colacios, Nathalie Andrieu-Abadie, Thierry Levade, Thomas Filleron, Jean-Pierre Delord, Maha Ayyoub, Nicolas Meyer, Bruno Ségui, Anne Montfort, Carine Dufau, Céline Colacios, Nathalie Andrieu-Abadie, Thierry Levade, Thomas Filleron, Jean-Pierre Delord, Maha Ayyoub, Nicolas Meyer, Bruno Ségui
Abstract
Immune checkpoint blockers (ICB) have revolutionized cancer therapy. However, complete response is observed in a minority of patients and most patients develop immune-related adverse events (irAEs). These include colitis, which can be treated with anti-tumor necrosis factor (TNF) antibodies such as Infliximab. In a recent issue of the Journal for ImmunoTherapy of Cancer, Badran et al. reported that co-administering Infliximab together with ICB to five cancer patients prevents colitis recurrence, with four of them exhibiting overall disease stability. The basis for this treatment strategy stemmed from our pre-clinical demonstration that TNF contributes to resistance to anti-PD-1 therapy. In agreement with this concept, we have shown that TNF blockers improve the anti-tumor therapeutic activity of ICB in mice and based on these findings we are currently evaluating the combination in melanoma patients enrolled in the TICIMEL clinical trial. Herein, (i) we discuss the scientific rationale for combining anti-TNF and ICB in cancer patients, (ii) comment on the paper published by Badran et al. and (iii) provide the TICIMEL clinical trial design.
Keywords: Anti-CTLA-4; Anti-PD-1; Certolizumab; Immune-related adverse events; Infliximab; Melanoma; Resistance; Tumor necrosis factor.
Conflict of interest statement
N.M. and J.P.D. have worked as investigators and/or consultants and/or speakers for: BMS, MSD, Amgen, Roche, GSK, Novartis, Pierre Fabre, AstraZeneca. B.S. has worked as an investigator, consultant and speaker for BMS. M.A. has worked as consultant and/or speaker for: AstraZeneca, BMS and Pierre Fabre. The authors declare that they have no other conflict of interest.
Figures
References
- Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. Overall survival with combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345–1356. doi: 10.1056/NEJMoa1709684.
- Lesage C, Longvert C, Prey S, Maanaoui S, Dreno B, Machet L, et al. Incidence and clinical impact of anti-TNFalpha treatment of severe immune checkpoint inhibitor-induced colitis in advanced melanoma: the Mecolit survey. J Immunother. 2019;42(5):175–179. doi: 10.1097/CJI.0000000000000268.
- Badran YR, Cohen JV, Brastianos PK, Parikh AR, Hong TS, Dougan M. Concurrent therapy with immune checkpoint inhibitors and TNFalpha blockade in patients with gastrointestinal immune-related adverse events. J Immunother Cancer. 2019;7(1):226. doi: 10.1186/s40425-019-0711-0.
- Ségui B, Bertrand F, Andrieu-Abadie N, Levade T, Colacios C, Rochaix P, et al., inventorsNew method for treating melanoma patent WO2015173259A1. 2015.
- Bertrand F, Rochotte J, Colacios C, Montfort A, Tilkin-Mariame AF, Touriol C, et al. Blocking tumor necrosis factor alpha enhances CD8 T-cell-dependent immunity in experimental melanoma. Cancer Res. 2015;75(13):2619–2628. doi: 10.1158/0008-5472.CAN-14-2524.
- Bertrand F, Montfort A, Marcheteau E, Imbert C, Gilhodes J, Filleron T, et al. TNFalpha blockade overcomes resistance to anti-PD-1 in experimental melanoma. Nat Commun. 2017;8(1):2256. doi: 10.1038/s41467-017-02358-7.
- Ségui B, Bertrand F, Andrieu-Abadie N, Levade T, Meyer N, Colacios C. inventorsMethods and pharmaceutical composition for the treatment of cancer patent WO2017129790A1. 2017.
- Perez-Ruiz E, Minute L, Otano I, Alvarez M, Ochoa MC, Belsue V, et al. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature. 2019;569(7756):428–432. doi: 10.1038/s41586-019-1162-y.
- Arora T, Padaki R, Liu L, Hamburger AE, Ellison AR, Stevens SR, et al. Differences in binding and effector functions between classes of TNF antagonists. Cytokine. 2009;45(2):124–131. doi: 10.1016/j.cyto.2008.11.008.
- Deeks ED. Certolizumab Pegol: a review in inflammatory autoimmune diseases. BioDrugs. 2016;30(6):607–617. doi: 10.1007/s40259-016-0197-y.
Source: PubMed